Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE ISSUED NOVEMBER 14, 2017 - INNOVUS PHARMACEUTICALS, INC. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): November 14,
2017
INNOVUS
PHARMACEUTICALS, INC.
(Exact name of
registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State or other
jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS Employer
Identification No.)
|
|
8845 Rehco Road, San Diego, CA
|
|
92122
|
|
(Address of
Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
Item 2.02 – Results of Operations and Financial
Condition
On
November 14, 2017, the Company issued a press release reporting our
financial results for the third quarter ended September 30, 2017.
The full text of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
Number
|
|
Description
|
|
|
Press
release issued November 14, 2017, reporting financial results for
the third quarter ended September 30, 2017
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
Date:
November 14,
2017
|
By:
|
/S/
Bassam
Damaj
|
|
|
|
|
Bassam Damaj,
CEO
|
|
|
|
|
|
|
EXHIBIT
INDEX
|
Exhibit
Number
|
|
Description
|
|
|
Press release
issued November 14, 2017, reporting financial results for the third
quarter ended September 30, 2017.
|